There are time-release pills that can be formulated to dissolve at a certain point in the alimentary canal. So theoretically you could formulate a pill which would not dissolve in the stomach but would wait until the small intestine, or the large intestine, whichever you're targeting, before it would dissolve and release the Brilacidin into the target site.

Why is this an advantage?

Because instead of killing off all the bacteria all the way down (including your stomach), you're only going to kill off bacteria in a smaller area. (Remember that we think it's the anti-inflammatory properties of Brilacidin that are what really helps the various forms of IBD so we're not necessarily targeting bacteria for death.) Because we are learning how important the "good" bacteria are for people's health, we don't want to kill off any more than we have to. Bacteria do things like produce B vitamins in your gut, and other beneficial stuff that we are just beginning to learn about.